No connection

Search Results

LUCD vs OABI

LUCD
Lucid Diagnostics Inc.
BEARISH
Price
$1.28
Market Cap
$218.1M
Sector
Healthcare
AI Confidence
95%
OABI
OmniAb, Inc.
BEARISH
Price
$1.48
Market Cap
$214.3M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
LUCD
--
OABI
--
Forward P/E
LUCD
-7.11
OABI
-4.93
P/B Ratio
LUCD
-3.87
OABI
0.8
P/S Ratio
LUCD
46.34
OABI
11.48
EV/EBITDA
LUCD
-5.38
OABI
-3.79

Profitability

Gross Margin
LUCD
-41.73%
OABI
98.38%
Operating Margin
LUCD
-931.58%
OABI
-147.35%
Profit Margin
LUCD
0.0%
OABI
0.0%
ROE
LUCD
-710.6%
OABI
-23.36%
ROA
LUCD
-87.2%
OABI
-13.04%

Growth

Revenue Growth
LUCD
25.6%
OABI
-22.5%
Earnings Growth
LUCD
--
OABI
--

Financial Health

Debt/Equity
LUCD
2.36
OABI
0.08
Current Ratio
LUCD
1.31
OABI
4.02
Quick Ratio
LUCD
1.27
OABI
3.78

Dividends

Dividend Yield
LUCD
--
OABI
--
Payout Ratio
LUCD
0.0%
OABI
0.0%

AI Verdict

LUCD BEARISH

LUCD exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness in profitability, leverage, and operating efficiency. The company suffers from catastrophic operating margins (-931.58%) and negative shareholder equity (P/B of -3.87), suggesting a precarious balance sheet. While revenue growth remains positive at 25.6%, there is a massive disconnect between the fundamental decay and the 'Strong Buy' analyst consensus. The valuation is unjustifiable on a data-driven basis, with a Price/Sales ratio of 46.34 for a company consistently missing earnings estimates.

Strengths
Consistent year-over-year revenue growth of 25.60%
Current ratio of 1.31 provides a minimal short-term liquidity buffer
Strong analyst target price ($4.10) suggesting high speculative potential
Risks
Negative book value (P/B -3.87) indicating liabilities exceed assets
Extreme operating losses with an operating margin of -931.58%
Severe financial health deterioration (Piotroski 1/9)
OABI BEARISH

OABI presents a contradictory profile: while the Piotroski F-Score of 6/9 indicates stable financial health and the balance sheet is strong with low debt and high liquidity, the operational data is alarming. Revenue is declining sharply (-22.5% YoY), and the stock is in a severe technical downtrend with bearish insider activity from the CEO and CFO. Despite a 'Strong Buy' analyst consensus and a high price target, the fundamental divergence between shrinking top-line growth and high Price/Sales valuation suggests significant risk.

Strengths
Strong liquidity with a Current Ratio of 4.02
Very low leverage (Debt/Equity of 0.08)
Exceptional Gross Margins (98.38%)
Risks
Significant revenue contraction (-22.5% YoY)
Severe operating losses (Operating Margin -147.35%)
Strong bearish insider selling by key executives

Compare Another Pair

LUCD vs OABI: Head-to-Head Comparison

This page compares Lucid Diagnostics Inc. (LUCD) and OmniAb, Inc. (OABI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile